This announcement was made alongside the reveal of positive Phase 3 results for Tanruprubart, a monoclonal antibody that can block C1q and can potentially halt neuroinflammation and nerve damage in ...

Annexon achieved primary endpoints in two Phase 3 studies for tanruprubart in treating Guillain-Barre Syndrome, setting the stage for a pre-BLA meeting ...

A hospital trust has apologised for the 'distress and trauma' after an 11-year-old girl has been awarded a £35 million ...

A single dose of investigational tanruprubart resulted in rapid, sustained improvement in disability compared with placebo in patients with Guillain-Barré syndrome (GBS), a phase III, ...

A live webcast of the Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with ...

Annexon presented additional data from the phase 3 pivotal trial of its tanruprubart, which the biotech is hoping to make the first approved targeted therapy for GBS. Last summer, Annexon ...

Peter Nicklin, Chairman of the Board, Hansa Biopharma said, In Q1, the Company delivered strong growth with total revenue of 66.3 MSEK and products sales of 65.7 MSEK. This represents a 39 percent ...

MinervaX is one company that wants to change this situation, which aims to prevent the spread of GBS infections using a vaccine instead of using an antibacterial agent. On the back of phase 1b ...

Tatiana Pinto, Associate Professor of Microbiology at the Federal University of Rio de Janeiro, tells us about the BactiVac networking opportunity that led to a five-year, international collaboration ...

Strong product sales and key progress in pipeline catalysts LUND, Sweden, April 24, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced ...

The Seyochung Area Students’ Union (SASU) convened a joint meeting with village leaders on April 17 at Old Monger Village to ...